Antitumor Activity of the Dual BET and CBP/EP300 Inhibitor NEO2734

Overview

Journal Blood Adv

Specialty Hematology

Date 2020 Sep 4

PMID 32882003

Citations 28

Authors

Filippo Spriano

Eugenio Gaudio

Luciano Cascione

Chiara Tarantelli

Federica Melle

Giovanna Motta

Valdemar Priebe

Andrea Rinaldi

Gaetanina Golino

Afua Adjeiwaa Mensah

Luca Aresu

Emanuele Zucca

Stefano Pileri

Michael Witcher

Bill Brown

Claes Wahlestedt

Francis Giles

Anastasios Stathis

Francesco Bertoni

Affiliations

Soon will be listed here.

Abstract

Bromodomain and extra-terminal domain (BET) proteins, cyclic adenosine monophosphate response element-binding protein (CBP), and the E1A-binding protein of p300 (EP300) are important players in histone acetylation. Preclinical evidence supports the notion that small molecules targeting these proteins individually or in combination can elicit antitumor activity. Here, we characterize the antitumor activity of the pan BET/CBP/EP300 inhibitor NEO2734 and provide insights into its mechanism of action through bromodomain-binding assays, in vitro and in vivo treatments of cancer cell lines, immunoblotting, and transcriptome analyses. In a panel of 60 models derived from different tumor types, NEO2734 exhibited antiproliferative activity in multiple cell lines, with the most potent activity observed in hematologic and prostate cancers. Focusing on lymphoma cell lines, NEO2374 exhibited a pattern of response and transcriptional changes similar to lymphoma cells exposed to either BET or CBP/EP300 inhibitors alone. However, NEO2734 was more potent than single-agent BET or CBP/EP300 inhibitors alone. In conclusion, NEO2734 is a novel antitumor compound that shows preferential activity in lymphomas, leukemias, and prostate cancers.

Citing Articles

Dysregulation of the p300/CBP histone acetyltransferases in human cancer.

Xu L, Xuan H, Shi X Epigenomics. 2025; 17(3):193-208.

PMID: 39929233 PMC: 11812348. DOI: 10.1080/17501911.2024.2447807.

The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors.

Wu X, Zhang X, Tang S, Wang Y Cell Biol Toxicol. 2025; 41(1):32.

PMID: 39825161 PMC: 11742294. DOI: 10.1007/s10565-024-09984-0.

Dual inhibition of BET and EP300 has antitumor activity in undifferentiated pleomorphic sarcomas and synergizes with ferroptosis induction.

Verbeke S, Bourdon A, Lafon M, Chaire V, Frederic B, Nait Eldjoudi A Transl Oncol. 2024; 52():102236.

PMID: 39681067 PMC: 11713734. DOI: 10.1016/j.tranon.2024.102236.

Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma.

Zou D, Feng S, Hu B, Guo M, Lv Y, Ma R Cell Biosci. 2024; 14(1):143.

PMID: 39580422 PMC: 11585172. DOI: 10.1186/s13578-024-01326-1.

Targeting lysine acetylation readers and writers.

Zhou M, Cole P Nat Rev Drug Discov. 2024; 24(2):112-133.

PMID: 39572658 PMC: 11798720. DOI: 10.1038/s41573-024-01080-6.

References

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

Spriano F, Stathis A, Bertoni F . Targeting BET bromodomain proteins in cancer: The example of lymphomas. Pharmacol Ther. 2020; 215:107631. DOI: 10.1016/j.pharmthera.2020.107631. View

Yeh T, OConnor G, Petteruti P, Dulak A, Hattersley M, Barrett J . Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors. Clin Cancer Res. 2017; 23(4):1025-1035. DOI: 10.1158/1078-0432.CCR-16-1658. View

Boi M, Todaro M, Vurchio V, Yang S, Moon J, Kwee I . Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget. 2016; 7(48):79637-79653. PMC: 5346742. DOI: 10.18632/oncotarget.12876. View

Dawson M, Kouzarides T, Huntly B . Targeting epigenetic readers in cancer. N Engl J Med. 2012; 367(7):647-57. DOI: 10.1056/NEJMra1112635. View

DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C . A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43(5):491-8. PMC: 3083463. DOI: 10.1038/ng.806. View

Adzhubei I, Schmidt S, Peshkin L, Ramensky V, Gerasimova A, Bork P . A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4):248-9. PMC: 2855889. DOI: 10.1038/nmeth0410-248. View

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K . Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016; 3(4):e186-95. DOI: 10.1016/S2352-3026(15)00247-1. View

10.

Hammitzsch A, Tallant C, Fedorov O, OMahony A, Brennan P, Hay D . CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015; 112(34):10768-73. PMC: 4553799. DOI: 10.1073/pnas.1501956112. View

11.

Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas A, Kwee I . Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica. 2019; 104(12):e558-e561. PMC: 6959164. DOI: 10.3324/haematol.2018.214957. View

12.

Vaser R, Adusumalli S, Leng S, Sikic M, Ng P . SIFT missense predictions for genomes. Nat Protoc. 2015; 11(1):1-9. DOI: 10.1038/nprot.2015.123. View

13.

Tarantelli C, Gaudio E, Arribas A, Kwee I, Hillmann P, Rinaldi A . PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clin Cancer Res. 2017; 24(1):120-129. DOI: 10.1158/1078-0432.CCR-17-1041. View

14.

Ceribelli M, Kelly P, Shaffer A, Wright G, Xiao W, Yang Y . Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A. 2014; 111(31):11365-70. PMC: 4128109. DOI: 10.1073/pnas.1411701111. View

15.

Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Corsini C . Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma. Haematologica. 2020; 105(8):e432-e436. PMC: 7395260. DOI: 10.3324/haematol.2020.249664. View

16.

Hogg S, Newbold A, Vervoort S, Cluse L, Martin B, Gregory G . BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Mol Cancer Ther. 2016; 15(9):2030-41. DOI: 10.1158/1535-7163.MCT-15-0924. View

17.

Conery A, Centore R, Neiss A, Keller P, Joshi S, Spillane K . Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife. 2016; 5. PMC: 4775225. DOI: 10.7554/eLife.10483. View

18.

Spriano F, Chung E, Gaudio E, Tarantelli C, Cascione L, Napoli S . The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clin Cancer Res. 2019; 25(16):5167-5176. DOI: 10.1158/1078-0432.CCR-18-2718. View

19.

Puissant A, Frumm S, Alexe G, Bassil C, Qi J, Chanthery Y . Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013; 3(3):308-23. PMC: 3672953. DOI: 10.1158/2159-8290.CD-12-0418. View

20.

Zhong H, Voll R, Ghosh S . Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell. 1998; 1(5):661-71. DOI: 10.1016/s1097-2765(00)80066-0. View